2019年欧洲肿瘤内科学会亚洲年会(ESMO ASIA 2019)将于11月22~24日在新加坡隆重召开。届时,各国肿瘤领域专家齐聚一堂,共襄盛举。本次大会有哪些重磅研究,小编带你先睹为快!
Proffered paper session - Thoracic cancers
LBA15 - CASPIAN亚洲人群分析:durvalumab+铂-依托泊苷一线治疗广泛期小细胞肺癌患者的总生存结果
Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia
时间:11月22日 02:30 PM - 02:42 PM
地点:Hall 406
讲者:Makoto Nishio
474O - MYSTIC研究:durvalumab(D)±tremelimumab(T)vs 化疗(CT)一线治疗亚洲转移性NSCLC患者的疗效和安全性
Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC
时间:11月22日 02:42 PM - 02:54 PM
地点:Hall 406
讲者:Byoung Chul Cho
475O - AURA3 Ⅲ期研究的总生存结果: 奥希替尼 vs 铂-培美曲塞用于EGFR T790M或EGFR-TKI治疗后进展的晚期非小细胞肺癌患者
Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
时间:11月22日 03:09 PM - 03:21 PM
地点:Hall 406
讲者:吴一龙
LBA16 - FLAURA研究:奥希替尼 vs EGFR-TKI一线治疗EGFR突变晚期NSCLC的最终总生存分析
Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
时间:11月22日 03:21 PM - 03:33 PM
地点:Hall 406
讲者:Byoung Chul Cho
LBA17 - FLAURA研究中,纵向监测循环肿瘤DNA(ctDNA)以早期发现晚期NSCLC的疾病进展和耐药
Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA
时间:11月22日 03:33 PM - 03:45 PM
地点:Hall 406
讲者:Thanyanan Reungwetwattana
Mixed Proffered paper session - Gastrointestinal tumours & Head and neck cancers
LBA7-阿替利珠单抗+贝伐珠单抗用于未经治疗的不可切除肝细胞癌患者的疗效和安全性
Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
时间:11月22日 04:30 PM - 04:45 PM
地点:Hall 404
讲者:Chih-Hung Hsu
286O - Ⅲ期KEYNOTE-048研究:帕博利珠单抗一线治疗复发/转移性头颈鳞癌亚洲vs非亚洲人群分析
Phase III KEYNOTE-048 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma: Asia vs non-Asia subgroup analysis
时间:11月22日 04:55 PM - 05:10 PM
地点:Hall 404
讲者:Natthapong Ngamphaiboon
287O - 结合血浆EB病毒DNA水平和TNM分期用于鼻咽癌辅助治疗分层的风险模型的构建和验证
Development and validation of a risk model integrating plasma Epstein-Barr virus DNA (EBV DNA) level and TNM stage for stratification of nasopharyngeal cancer (NPC) to adjuvant therapy
时间:11月22日 05:20 PM - 05:35 PM
地点:Hall 404
讲者:Edwin P. Hui
Presidential session
LBA1 - 布加替尼vs克唑替尼用于未经ALK抑制剂治疗的晚期ALK+ NSCLC:Ⅲ期ALTA-1L研究的更新结果
Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial
时间:11月23日 11:00 AM - 11:15 AM
地点:Hall 406
讲者:Ross Camidge
LBA2 - TATTON扩展队列:奥希替尼联合savolitinib用于EGFR-TKI治疗后进展的EGFR突变、MET阳性NSCLC患者的Ib期研究
TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI
时间:11月23日 11:25 AM - 11:40 AM
地点:Hall 406
讲者:Ji-Youn Han
LBA3 - IMbrave150 Ⅲ期研究:阿替利珠单抗+贝伐珠单抗vs索拉非尼一线治疗不可切除肝细胞癌患者的疗效和安全性
IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
时间:11月23日 11:50 AM - 12:05 PM
地点:Hall 406
讲者:Ann-Lii Cheng
Proffered paper session - Breast cancer
25O - FinXX研究:免疫结构对三阴性乳腺癌患者辅助卡培他滨应答的影响
Effects of immune architecture on response to adjuvant capecitabine in triple negative breast cancer (FinXX trial)
时间:11月23日 09:00 AM - 09:12 AM
地点:Hall 405
讲者:Douglas A. Hinerfeld
LBA6 - 首个中国生产的曲妥珠单抗生物类似药HLX02治疗乳腺癌的全球Ⅲ期临床研究达到主要终点
First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer
时间:11月23日 09:12 AM - 09:24 AM
地点:Hall 405
讲者:徐兵河
1O - KATHERINE Ⅲ期研究:HER2阳性乳腺癌新辅助化疗后残留浸润性疾病的中国患者应用T-DM1和曲妥珠单抗的比较
Trastuzumab emtansine (T-DM1) vs trastuzumab (H) in Chinese patients (pts) with residual invasive disease after neoadjuvant chemotherapy for HER2-positive breast cancer (BC) in the phase III KATHERINE study
时间:11月23日 09:34 AM - 09:46 AM
地点:Hall 405
讲者:Chiunsheng Huang
37O - IMpassion130亚组分析:阿替利珠单抗+纳米紫杉醇用于亚洲国家晚期三阴性乳腺癌患者治疗
Subgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries
时间:11月23日 09:56 AM - 10:08 AM
地点:Hall 405
讲者:Hiroji Iwata
38O - Talazoparib vs医生选择的化疗方案用于HER2-、胚系BRCA1/2突变(gBRCA1/2mut)亚洲晚期乳腺癌患者——Ⅲ期EMBRACA数据
Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): Data from phase III EMBRACA
时间:11月23日 10:08 AM - 10:20 AM
地点:Hall 405
讲者:Kyung-Hun Lee
Proffered paper session - Gynaecological cancers
224O - 奥拉帕利用于新诊断BRCA突变卵巢癌患者维持治疗的SOLO1 Ⅲ期研究中,以患者为中心的结果支持PFS延长的临床获益
Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)
时间:11月24日 09:15 AM - 09:25 AM
地点:Room 324
讲者:Michael L. Friedlander
225O - 影像学疾病进展对一线含铂化疗后接受奥拉帕利或安慰剂维持治疗的BRCA突变晚期卵巢癌患者健康状态的影响
Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy
时间:11月24日 09:25 AM - 09:35 AM
地点:Room 324
讲者:Michael L. Friedlander
LBA10 – Ⅲ期PAOLA-1/ENGOT-ov25研究:奥拉帕利+贝伐珠单抗用于新诊断晚期卵巢癌含铂化疗+贝伐珠单抗治疗后的一线维持治疗
Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
时间:11月24日 09:35 AM - 09:50 AM
地点:Room 324
讲者:Keiichi Fujiwara
LBA11 – 马来西亚关于卵巢癌患者BRCA1/2基因检测的主流遗传咨询
Mainstreaming genetic counselling for genetic testing of BRCA1/2 in ovarian cancer patients in Malaysia (MaGIC study)
时间:11月24日 10:05 AM - 10:17 AM
地点:Room 324
讲者:Sook Yee Y. Yoon
226O – 卵巢癌、原发性腹膜癌和输卵管癌患者胚系BRCA1和BRCA2突变和变异发生率:一项印度的多中心研究
Prevalence of germline BRCA1 and BRCA2 mutations and variants among ovarian, primary peritoneal and fallopian tube cancer patients: A multicentre Indian study
时间:11月24日 10:17 AM - 10:29 AM
地点:Room 324
讲者:Sudeep Gupta
更多ESMO Asia报道,敬请继续关注肿瘤医生APP